earnings
FB
NASDAQ · FBIO
Fortress Biotech, Inc.
Healthcare · Biotechnology
$2.51
Up+$0.00 (+0.00%)
Updated Sep 18, 2026, 10:22 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 90.78M
- P/E ratio
- 11.44
- Dividend yield
- 0.00%
- 52-week range
- $2.18 – $3.84
- Volume
- 167.54K
- Avg. volume
- 760.74K
Price performance
FBIO price history
1M range · 20 trading sessions · Daily adjusted prices
FBIO closed at $2.51 after 20 trading sessions, down 9.39% for the selected period.
- Last close
- $2.51
- Period change
- -9.39%
- Period low
- $2.46
- Period high
- $2.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $2.49 | $2.51 | $2.44 | $2.51 | 167.54K |
| Sep 16, 2026 | $2.48 | $2.505 | $2.41 | $2.46 | 352.89K |
| Sep 15, 2026 | $2.51 | $2.5299 | $2.46 | $2.49 | 225.32K |
| Sep 14, 2026 | $2.50 | $2.54 | $2.46 | $2.53 | 226.48K |
| Sep 11, 2026 | $2.59 | $2.6246 | $2.52 | $2.52 | 209.7K |
| Sep 10, 2026 | $2.60 | $2.625 | $2.53 | $2.57 | 315.55K |
| Sep 9, 2026 | $2.67 | $2.70 | $2.62 | $2.63 | 280.4K |
| Sep 8, 2026 | $2.69 | $2.75 | $2.67 | $2.71 | 263.05K |
| Sep 4, 2026 | $2.68 | $2.74 | $2.675 | $2.72 | 168.14K |
| Sep 3, 2026 | $2.75 | $2.76 | $2.695 | $2.71 | 148.11K |
| Sep 2, 2026 | $2.67 | $2.74 | $2.67 | $2.73 | 279.77K |
| Sep 1, 2026 | $2.69 | $2.77 | $2.63 | $2.68 | 605.78K |
| Aug 31, 2026 | $2.795 | $2.795 | $2.69 | $2.735 | 326.34K |
| Aug 28, 2026 | $2.80 | $2.81 | $2.745 | $2.77 | 309.69K |
| Aug 27, 2026 | $2.84 | $2.875 | $2.77 | $2.80 | 463.48K |
| Aug 26, 2026 | $2.79 | $2.88 | $2.78 | $2.81 | 395.83K |
| Aug 25, 2026 | $2.95 | $2.9902 | $2.78 | $2.83 | 451.34K |
| Aug 24, 2026 | $2.83 | $2.99 | $2.83 | $2.93 | 603.9K |
| Aug 21, 2026 | $2.80 | $2.875 | $2.7937 | $2.87 | 202.72K |
| Aug 20, 2026 | $2.80 | $2.87 | $2.75 | $2.77 | 323.76K |
Latest FBIO news
The latest Smart Investors Daily articles mentioning FBIO.
Stock researchResearch & News · Competitors
Loading stock research…

